SCHEMBL786755

SCHEMBL786755

Clc1ccccc1-c1cc(Cl)c2ccncc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 7/20 0.51
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
LATS2 Q9NRM7 3/20 0.41
IDO1 P14902 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LIMK1 P53667 1/20 0.40
F10 P00742 1/20 0.39
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
CDK2 P24941 1/20 0.39
PDE2A O00408 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE11A Q9HCR9 1/20 0.39
PDE10A Q9Y233 1/20 0.39
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29650563 0.80 LATS1 (0.60) LATS1LATS2
SCHEMBL20547756 0.80 LATS1 (0.60) LATS1LATS2
SCHEMBL20574275 0.79 LATS1 (0.56) LATS1LATS2
SCHEMBL11374540 0.76 HSP90AA1 (0.49) LATS1HSP90AA1HSP90AB1IDO1NPC1
SCHEMBL246231 0.76 LATS1 (0.43) LATS1LATS2IDO1
SCHEMBL20574285 0.75 LATS1 (0.59) LATS1LATS2MAPK14
SCHEMBL786535 0.75 CYP1A2 (0.50) LATS1MEN1KMT2ALATS2L3MBTL1
SCHEMBL6694034 0.75 CYP19A1 (0.41) LATS1NPC1RAB9ACDK2
SCHEMBL26743064 0.74 LATS1 (0.50) LATS1LATS2
SCHEMBL11371493 0.73 HSP90AA1 (0.49) HSP90AA1HSP90AB1IDO1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 LATS1 1086/4885HSP90AA1 4129/4885HSP90AB1 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.